Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (1745)	9/28/2000 1:09:09 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Spekulatius, I've been in and out of SUPG, and currently have no position. My one concern with them was their tendency to report results with a somewhat more favorable slant than was perhaps justified by the data. (For example, reporting results for only "evaluable" patients, where their definition of evaluable discarded many patients who didn't complete a couple of rounds of therapy.) The stock is not real expensive, though, and so maybe one can overlook some over-enthusiasm. I'd maybe be a buyer on weakness. I do still hold some MOGN, which is a stock in the same general category. Peter